Research programme: GABA A alpha-5 modulators - AgeneBio

Drug Profile

Research programme: GABA A alpha-5 modulators - AgeneBio

Latest Information Update: 11 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Johns Hopkins University
  • Developer AgeneBio
  • Class Neuroprotectants; Small molecules
  • Mechanism of Action GABA A alpha 5 receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Alzheimer's disease; Autistic disorder; Mild cognitive impairment; Schizophrenia

Most Recent Events

  • 30 Jun 2017 Preclinical development is ongoing for Alzheimer's disease and Mild cognitive impairment USA
  • 26 Aug 2010 Preclinical research in Alzheimer's disease in USA (unspecified route)
  • 26 Aug 2010 Preclinical research in Mild cognitive impairment in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top